Region’s first successful bone marrow transplant on MS patient performed in Abu Dhabi
The Abu Dhabi Stem Cells Center has performed the region’s first successful bone marrow transplant on a patient suffering from multiple sclerosis, Emirates News Agency reported.
This achievement marks a major advance in cell therapy and regenerative medicine capabilities to treat a range of diseases, including cancer and immune disorders.
Doctors at ADSCC performed the region’s first autologous hematopoietic stem cell transplantation on a patient with MS earlier this month and the patient has since reported an improvement in her overall condition. The treatment aims to “reset” a person’s immune system and can be used for those with relapsing forms of MS.
“We are extremely proud of our achievement at the Abu Dhabi Stem Cells Center to become the first centre in the region to perform the BMT on a MS patient. It fills us with great pride to make such a life-saving treatment here in Abu Dhabi,” said ADSCC’s CEO Dr Yendry Ventura.
The AHSCT procedure carried out by ADSCC is a “standard of care” and not just a “clinical option” under the updated European Group for Blood & Marrow Transplantation and American Society for Blood and Marrow Transplantation guidelines from 2019, which reviewed the clinical evidence of AHSCT on MS patients.
The transplant success follows ADSCC’s ground-breaking work on COVID-19 treatments during the pandemic. These included UAECell19, which was used as a stem cell therapy to help regenerate lung capacity in thousands of COVID-19 patients.
Doctors at ADSCC performed the region’s first autologous hematopoietic stem cell transplantation on a patient with MS earlier this month and the patient has since reported an improvement in her overall condition. The treatment aims to “reset” a person’s immune system and can be used for those with relapsing forms of MS.
“We are extremely proud of our achievement at the Abu Dhabi Stem Cells Center to become the first centre in the region to perform the BMT on a MS patient. It fills us with great pride to make such a life-saving treatment here in Abu Dhabi,” said ADSCC’s CEO Dr Yendry Ventura.
The AHSCT procedure carried out by ADSCC is a “standard of care” and not just a “clinical option” under the updated European Group for Blood & Marrow Transplantation and American Society for Blood and Marrow Transplantation guidelines from 2019, which reviewed the clinical evidence of AHSCT on MS patients.
The transplant success follows ADSCC’s ground-breaking work on COVID-19 treatments during the pandemic. These included UAECell19, which was used as a stem cell therapy to help regenerate lung capacity in thousands of COVID-19 patients.
